Clinical trial
Combination Chemotherapy for Metastatic Breast Cancer
NCT00191815 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191815 |
|---|---|
| Title | Combination Chemotherapy for Metastatic Breast Cancer |
| Official title | Phase II Study of Gemcitabine Plus Cisplatin as First-line Treatment of Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, cisplatin |
| Enrollment | 70 |
| Start date | Oct 1, 2002 |
| Completion | Oct 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 11, 2009 |
| Countries | Germany, Russia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: